AstraZenecaの空売り状況は、投資家がAstraZenecaの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

AstraZeneca (NASDAQ:AZN) 株価情報, 空売り情報

AstraZeneca

A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, immunology and rare diseases. The majority of sales come from international markets with the United States representing close to one third of its sales.

AstraZeneca PLC - American Depositary Shares

AstraZeneca PLC

Precidian ETFs Trust AstraZeneca PLC ADRhedged

AZN Capital Corp

H.C. Wainwright &amp; Co. initiated coverage on Thursday for Perspective Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CATX#NASDAQ">CATX</a>), a clinical-stage biotechnology company advancing &#8220;targeted radiotherapy agents&#8221; for cancer treatment.
Analyst Robert Burns initiated a Buy rating and a <a href="https://www.benzinga.com/quote/CATX/analyst-ratings" target="_blank" rel="noreferrer noopener">price target of $10</a>.
The company&#8217;s pipeline comprises:
<ul>
<li>VMT01/02 for melanoma, which is being studied as both monotherapy and in combination with Opdivo (nivolumab).</li>
<li>VMT-α-NET for various neuroendocrine cancers and other SSTR2-expressing tumors.</li>
<li>PSV359 for multiple solid tumor types.</li>
<li>PSV40X for prostate cancer.</li>
</ul>
The company&#8217;s melanoma (VMT01) and neuroendocrine tumor (VMT-α-NET) programs have entered Phase 1/2a imaging and therapy trials for metastatic melanoma and neuroendocrine tumors.
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41634528/positive-outlook-for-novartis-as-company-capitalizes-on-growing-treatment-opportuni" rel="noreferrer noopener">Positive Outlook For Novartis As Company Capitalizes On Growing Treatment Opportunities, Analyst Highlights</a>
In January, Perspective Therapeutics&nbsp;revealed updated interim results from its ongoing Phase 1/2a trial of&nbsp;[212Pb]VMT-α-NET. Anti-tumor activities have been observed&nbsp;with a longer follow-up. As of the data cut-off date of Jan. 10, 2025, there were two unconfirmed responses and one confirmed response, <a href="https://www.benzinga.com/general/biotech/25/01/43197970/perspective-therapeutics-touts-encouraging-updated-data-from-gastrointestinal-cancer-trial-stock-soars" target="_blank" rel="noreferrer noopener">as in Cohort 2</a>.
H.C. Wainwright &amp; Co. writes that from a safety perspective, 212Pb-VMT-α-NET appears to be relatively benign at the dose levels tested thus far.
The analyst writes that PSV359 and VMT01/02 constitute upside potential. Burns also notes that in preclinical experiments, VMT01/02 demonstrated high response rates in multiple tested models and &gt;70% complete and durable response when combined with PD1 immunotherapy in a model highly resistant to checkpoint inhibitors
Perspective Therapeutics disclosed initial preclinical results for its FAPtargeted asset, PSV359 and views the preclinical anti-tumor efficacy as encouraging. The analyst also writes it is difficult to benchmark it against 177LuFAP-2286 and PNT6555 because these experiments were performed in a completely different mouse model.
&#8220;Additionally, when we think about potential targets for targeted radioligand therapy (TRT), we believe that most of the targets being pursued by ADCs and/or cell therapy are viable targets for TRT. As such, we view the targeted radioligand space as analogous to where the ADC space was a few years ago,&#8221; Burns writes.
Here are some M&amp;A in the radiopharmaceutical therapeutics&nbsp;space:
<ul>
<li>In 2023, Bristol Myers Squibb &amp; Co&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) acquired&nbsp;RayzeBio&nbsp;for $62.50 per share in cash, for a total equity value of approximately $4.1 billion, or $3.6 billion net of&nbsp;<a href="https://www.benzinga.com/general/biotech/23/12/36382899/bristol-myers-squibb-takes-on-novartis-eli-lilly-with-rayzebio-4b-deal-in-radiopharmaceuticals" target="_blank" rel="noreferrer noopener">estimated cash acquired</a>.&nbsp;</li>
<li>In 2023, Eli Lilly And Co&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) acquired&nbsp;POINT Biopharma Global for $12.50 per share in cash, an aggregate of&nbsp;<a href="https://www.benzinga.com/general/biotech/23/10/35060421/why-is-cancer-treatment-focused-point-biopharma-stock-trading-higher-today" target="_blank" rel="noreferrer noopener">approximately $1.4 billion</a>.</li>
<li>In 2024, AstraZeneca Plc&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>) acquired&nbsp;Fusion Pharmaceuticals for $21 per share in cash plus a non-transferable contingent value right of $3 per share in cash payable upon the achievement of a&nbsp;<a href="https://www.benzinga.com/general/biotech/24/03/37818128/astrazenecas-2-4b-fusion-pharmaceuticals-acquisition-signals-shift-in-efforts-from-traditional-re" target="_blank" rel="noreferrer noopener">specified regulatory milestone</a>.</li>
</ul>
CATX Price Action: Perspective Therapeutics stock is down 0.75% at $2.64 at publication Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/03/44306287/village-farms-ceo-highlights-momentum-for-profitable-expansion-clocks-11-jump-in-q4-sales" target="_blank" rel="noreferrer noopener">Village Farms CEO Highlights Momentum For Profitable Expansion, Clocks 11% Jump In Q4 Sales</a></li>
</ul>
Photo: S_fam photo via Shutterstock

Analyst Color

Biotech

News

Health Care

Initiation

Analyst Ratings

Trading Ideas

General

CATX

Perspective Therapeutics' Cancer-Focused Radiotherapy Portfolio Has Upside Potentional, Says Analyst

On Thursday, Vivani Medical, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VANI#NASDAQ">VANI</a>) announced the administration of its first GLP-1 (exenatide, NPM-115) implant in the LIBERATE-1 <a target="_blank" href="https://www.benzinga.com/topic/weight-loss" rel="noreferrer noopener">trial in Australia</a>.
Vivani's lead program, NPM-115, utilizes a miniature, six-month, subdermal, GLP-1 (exenatide) implant under development for chronic weight management in obese or overweight individuals.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/health-care/25/03/44273204/exclusive-vivani-medical-to-spin-off-cortigent-neurostimulation-business-to-create-better-focus-on-individual-entities-and-shareholder-value" rel="noreferrer noopener">EXCLUSIVE: Vivani Medical To Spin Off Cortigent Neurostimulation Business To Create Better Focus On Individual Entities And Shareholder Value</a>
The company also announced full enrollment in the LIBERATE-1 study, which was achieved four weeks after the first subject enrolled, and reaffirmed that top-line results should be available in mid-2025.
In December, Vivani Medical initiated screening and enrollment at two centers in Australia for the first-in-<a target="_blank" href="https://www.benzinga.com/general/biotech/24/12/42576062/exclusive-vivani-medical-initiates-first-human-clinical-trial-with-glp-1-implant-for-weight-loss-in-australia" rel="noreferrer noopener">human LIBERATE-1 trial</a>.
The LIBERATE-1 study is exploring the full pharmacokinetic profile of NPM-115, which has demonstrated consistently smooth and minimally fluctuating drug release in vitro and in animal models.
LIBERATE-1 is a Phase 1, first-in-human study of a miniature, ultra-long-acting GLP-1 (exenatide) implant to investigate the safety, tolerability, and full pharmacokinetic profile in obese or overweight subjects.
The trial will enroll participants who are intended to be titrated on weekly semaglutide injections for 8 weeks (0.25 mg/week for 4 weeks followed by 0.5 mg/week for 4 weeks) before being randomized to receive a single administration of Vivani's exenatide implant (NPM-115, n=8), weekly exenatide injections (Bydureon BCise, n=8), or weekly 1 mg semaglutide injections (Wegovy, n=8) for 9-week treatment duration.
Vivani also expects these results to support the potential application of a GLP-1 (exenatide) implant for type 2 diabetes and other diseases for which GLP-1 treatment has demonstrated or will demonstrate clinical benefit.
AstraZeneca Plc's (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>) Bydureon BCise (exenatide 2 mg prolonged-release suspension for injection) is indicated for type-2 diabetes.
Novo Nordisk A/S' (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) semaglutide is approved as Ozempic and Wegovy for diabetes and weight loss, respectively.
Price Action: VANI stock is down 2.74% at $1.01 during the premarket session at the last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/25/03/44290984/gsk-and-pfizer-viiv-healthcares-mid-stage-study-shows-strong-hiv-viral-suppression-with-long-acting-therapy" target="_blank" rel="noreferrer noopener">GSK, Pfizer's ViiV Healthcare Shows Strong HIV Viral Suppression In Latest Study</a></li>
</ul>

Market-Moving Exclusives

Exclusives

VANI

EXCLUSIVE: Vivani Medical Announces First Implant In Early-Stage Human Study Of GLP-1 Implant For Obesity

On Tuesday, Ionis Pharmaceuticals Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IONS#NASDAQ">IONS</a>)&nbsp;and Ono Pharmaceutical Co., Ltd entered into a license agreement in which Ono obtains exclusive global rights for the development and commercialization of sapablursen, an investigational RNA-targeted <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/b44265240/ionis-and-ono-announce-global-license-agreement-for-sapablursen-in-polycythemia-vera" rel="noreferrer noopener">medicine for polycythemia vera (PV)</a>.
PV is a rare hematologic disease characterized by the overproduction of red blood cells, significantly increasing the risk of serious blood clots, especially in critical organs like the <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">lungs, heart and brain</a>.
Sapablursen is currently being evaluated in adults living with PV in the fully enrolled Phase 2 IMPRSSION study.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/02/43818962/ionis-pharmaceuticals-says-2024-revenue-exceeds-guidance-on-sales-from-diverse-sources-forecasts-over-600-million-in-2025-sales" rel="noreferrer noopener">Ionis Pharmaceuticals Q4 Revenue Growth Exceeds Guidance, Forecasts Over $600 Million In 2025 Sales</a>
Sapablursen received FDA Fast Track designation and orphan drug designation in 2024.
Under the agreement, Ionis will receive a $280 million upfront payment, potentially earning up to $660 million in additional payments based on the achievement of development, regulatory, and sales milestones.
Ionis is also eligible to earn royalties in the mid-teen percentage range on annual net sales of sapablursen.
Ionis will be responsible for completing the ongoing Phase 2 IMPRSSION study, while Ono will be solely responsible for subsequent development, regulatory filings, and commercialization.
&#8220;Ionis remains committed to advancing the wholly owned medicines we choose to commercialize ourselves, which includes our first independent launch currently underway and three additional anticipated launches in the next three years. Streamlining our Ionis-owned portfolio provides financial flexibility, supporting our commitment to invest in and focus on our near and mid-term commercial opportunities and generate substantial revenue growth,&#8221; said Brett P. Monia, Ph.D., CEO of Ionis.
Earlier this week, the European Union approved Ionis Pharmaceutical and AstraZeneca plc&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>) Wainzua (eplontersen) for hereditary transthyretin-mediated amyloidosis in adult patients with stage 1 or stage 2 polyneuropathy, commonly referred to as <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/b44215431/wainzua-eplontersen-approved-in-the-eu-for-the-treatment-of-hereditary-transthyretin-mediated-amyl" rel="noreferrer noopener">hATTR-PN or ATTRv-PN</a>.
Price Action: At the last check on Wednesday, IONS stock was up 1.24% at $33.54.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/media/25/03/44275158/palantir-ceo-becomes-top-earning-tech-boss-as-ai-stock-soars-216-report" target="_blank" rel="noreferrer noopener">Palantir CEO Becomes Top-Earning Tech Boss As AI Stock Soars 216%: Report</a></li>
</ul>

Contracts

Movers

IONS

Ionis Pharmaceuticals Partners With Japan-Based Ono Pharmaceutical For Rare Blood Disease Drug In Over $800 Million Deal

<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.ionis.com%2F&amp;esheet=54221346&amp;newsitemid=20250310238705&amp;lan=en-US&amp;anchor=Ionis+Pharmaceuticals%2C+Inc.&amp;index=1&amp;md5=e0374aeb2777f987ad0557639a313466">Ionis Pharmaceuticals, Inc. </a>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IONS#NASDAQ">IONS</a>) announced today that Ionis and AstraZeneca's WAINZUA (eplontersen) has been approved in the European Union (EU) for the treatment of hereditary transthyretin-mediated amyloidosis in adult patients with stage 1 or stage 2 polyneuropathy, commonly referred to as hATTR-PN or ATTRv-PN. WAINZUA is the only approved medicine in the EU for the treatment of ATTRv-PN that can be self-administered monthly via an auto-injector.
The approval by the European Commission (EC) follows the <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fir.ionis.com%2Fnews-releases%2Fnews-release-details%2Fwainzua-eplontersen-recommended-approval-eu-chmp-treatment&amp;esheet=54221346&amp;newsitemid=20250310238705&amp;lan=en-US&amp;anchor=positive+opinion&amp;index=2&amp;md5=6dade3e35e1b46e15403a56558a1d0e4">positive opinion</a> of the Committee for Medicinal Products for Human Use (CHMP). The approval is based on the positive NEURO-TTRansform Phase 3 trial which showed that through 66 weeks, patients treated with WAINZUA demonstrated consistent and sustained benefit on the co-primary endpoints of serum transthyretin (TTR) concentration and neuropathy impairment measured by modified Neuropathy Impairment Score +7 (mNIS+7), and key secondary endpoint of quality of life (QoL) on the Norfolk Quality of Life Questionnaire-Diabetic Neuropathy (Norfolk QoL-DN) versus external placebo. WAINZUA continued to demonstrate a favorable safety and tolerability profile throughout the NEURO-TTRansform trial.
ATTRv-PN is a debilitating disease that leads to peripheral nerve damage with motor disability within five years of diagnosis and, without treatment, is generally fatal within a decade. WAINZUA is a once-monthly RNA-targeted medicine designed to reduce the production of TTR protein at its source.

Government

Regulations

Ionis and AstraZeneca Win EU Approval for WAINZUA, a Self-Injectable Treatment for Rare Nerve Disease

<ul>
<li>CDC study follows measles outbreak amid declining vaccination rates</li>
<li>Kennedy's mixed messages on vaccines raise concerns</li>
<li>Autism rise attributed to broader screening, not vaccines</li>
</ul>
March 7 - The U.S. Centers for Disease Control and Prevention is planning a large study into potential connections between vaccines and autism, two sources familiar with the matter told Reuters, despite extensive scientific research that has disproven or failed to find evidence of such links.
It is unclear whether U.S. Health Secretary Robert F. Kennedy Jr, who has long promoted <a href="reuters://REALTIME/verb=NewsStory/ric=nL2N3PH1HA">anti-vaccine views</a>, is involved in the planned CDC study or how it would be carried out. The CDC and the Department of Health and Human Services were not immediately available for comment.
The CDC's move comes amid one of the largest <a href="reuters://REALTIME/verb=NewsStory/ric=nL3N3PN1WV">measles outbreaks</a> the U.S. has seen in the past decade, with more than 150 cases and two deaths in Texas and New Mexico. The outbreak has been fueled by declining vaccination rates in parts of the United States where parents have been falsely persuaded that such shots do more harm than good.
Kennedy, whose role includes authority over the CDC, has long sowed doubt over the safety of the combined vaccine for measles, mumps and rubella (MMR). In a cabinet meeting last week, Kennedy initially downplayed news that a school-aged child had died of measles in Texas, the first such death in a decade, calling such outbreaks ordinary and failing to mention the role of vaccination to prevent measles.
Over the weekend, Kennedy published an opinion piece on Fox News that promoted the role of vaccination, but also told parents vaccination was a personal choice and urged them to consult with their physician.
Kennedy did not immediately respond to a request for comment.
Autism diagnoses in the United States have increased significantly since 2000, intensifying public concern.
Many researchers attribute the <a href="reuters://REALTIME/verb=NewsStory/ric=nL1N3NJ17A">rise in diagnoses</a> to more widespread screening and the inclusion of a broader range of behaviors to describe the condition. But some public figures have popularized the idea that vaccines are to blame, an idea stemming from a since-debunked study from British researcher Andrew Wakefield in the late 1990s that connected a rise in autism diagnoses with widespread use of the MMR shot.
The causes of autism are unclear. No rigorous studies have found links between autism and vaccines or medications, or their components such as thimerosal or formaldehyde.
There is widespread speculation among scientists that its neurological characteristics may develop in utero, when the fetal brain is being wired. Studies have linked autism to maternal factors in pregnancy, and some research suggests a link to birth complications and timing.
President Donald Trump, in an address to Congress this week, cited the rise in autism among children. "So, we're going to find out what it is, and there's nobody better than Bobby and all of the people that are working with you," Trump said, referring to Kennedy.
Kennedy's anti-vaccine views have drawn concern among some Republicans. During Kennedy's confirmation hearing Senator Bill Cassidy, a Louisiana Republican and physician, suggested that the nominee disavow any links between vaccines and autism.
Kennedy denied that he was anti-vaccine, but did not acknowledge that such a link had been debunked.
This week Cassidy questioned Trump's nominee to lead the National Institutes of Health, Dr. Jay Bhattacharya, over his stance on investigating a potential link between autism and childhood vaccinations.
"I don't generally believe there is a link, based on my reading of the literature," Bhattacharya said. "But we do have a sharp rise in autism rates, and I don't think any scientist really knows the cause of it. I would support a broad scientific agenda based on data to get an answer to that."

BNTX

MRNA

'U.S. CDC Plans Large Study Into Potential Connections Between Vaccines And Autism, Sources Say' - Reuters News

On Friday, AstraZeneca Plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>) released high-level results from the MATTERHORN Phase 3 trial evaluating&nbsp;Imfinzi&nbsp;(durvalumab) as a perioperative treatment for patients with resectable Stage II-IVA gastric and gastroesophageal <a target="_blank" href="https://www.benzinga.com/general/biotech" rel="noreferrer noopener">junction (GEJ) cancers</a>.
The <a target="_blank" href="https://www.astrazeneca.com/media-centre/press-releases/2025/imfinzi-improved-efs-in-early-stage-gastric-cancer.html" rel="noreferrer noopener">trial</a> showed that perioperative treatment with Imfinzi&nbsp;in combination with standard-of-care FLOT (fluorouracil, leucovorin, oxaliplatin, and docetaxel) chemotherapy demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of event-free survival (EFS).
Also Read: <a target="_blank" href="https://www.benzinga.com/25/02/43742302/astrazenecas-imfinzi-perioperative-regimen-shows-improved-survival-outcomes-in-bladder-cancer-patients" rel="noreferrer noopener">AstraZeneca&#8217;s Imfinzi Perioperative Regimen Shows Improved Survival Outcomes In Bladder Cancer Patients</a>
Patients were treated with neoadjuvant&nbsp;Imfinzi&nbsp;in combination with chemotherapy before surgery, followed by adjuvant&nbsp;Imfinzi&nbsp;in combination with chemotherapy, then&nbsp;Imfinzi&nbsp;monotherapy.
The trial evaluated this regimen versus perioperative chemotherapy alone for patients with resectable, early-stage and locally advanced (Stages II, III, IVA) gastric and gastroesophageal junction (GEJ) cancers.
A strong trend was observed for the secondary endpoint of overall survival (OS) in favor of the&nbsp;Imfinzi-based regimen. The trial will follow OS, which will be formally assessed at the final analysis.
Gastric cancer is the fifth leading cause of cancer death globally, with nearly one million people diagnosed each year.
In 2024, there were roughly 43,000 drug-treated patients in the US, European Union, and Japan with early-stage and locally advanced gastric or GEJ cancer. Approximately 62,000 patients in these regions are expected to be newly diagnosed in this setting by 2030.
The safety profile for&nbsp;Imfinzi&nbsp;and FLOT chemotherapy was consistent with the known profiles of each medicine, and there were no new safety findings.
In a&nbsp;<a target="_blank" href="https://www.astrazeneca.com/media-centre/press-releases/2023/imfinzi-plus-chemotherapy-doubled-pathologic-complete-response-rate-resectable-early-stage-gastric-gastroesophageal-junction-cancers-vs-chemotherapy.html" rel="noreferrer noopener">previously reported</a> interim analysis for the key secondary endpoint of pathologic complete response (pCR), the&nbsp;Imfinzi&nbsp;combination more than doubled the pCR rate compared to neoadjuvant chemotherapy alone.
Price Action: AZN stock is up 0.22% at $77.64 during the premarket session at the last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/03/44165610/victorias-secret-delivers-solid-q4-results-but-ceo-warns-of-near-term-headwinds" target="_blank" rel="noreferrer noopener">Victoria&#8217;s Secret Delivers Solid Q4 Results, But CEO Warns Of &#8216;Near-Term Headwinds&#8217;</a></li>
</ul>
Image by Robert Way via Shutterstock

Large Cap

AstraZeneca's Imfinzi-Based Regimen Shows Improved Event-Free Survival In Early-Stage Gastric Cancer Patients

AstraZeneca Says IMFINZI (durvalumab)-based Regimen Demonstrated Improvement In Event-free Survival In Resectable Early-stage Gastric And Gastroesophageal Junction Cancers

JP Morgan analyst Anupam Rama issued a note on Thursday maintaining a positive outlook on Kiniksa Pharmaceuticals International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KNSA#NASDAQ">KNSA</a>), citing Arcalyst&#8217;s strong commercial performance and the<a href="https://www.benzinga.com/general/biotech"> company's focused pipeline. </a>
JP Morgan maintains the Overweight rating with a <a href="https://www.benzinga.com/quote/KNSA/analyst-ratings" target="_blank" rel="noreferrer noopener">price target of $40</a>.
Rama values Kiniksa shares in the low-$30s on Arcalyst alone and estimates a range in the high-$30s to low-$40s when including probability-adjusted KPL-387. The analyst believes the strategic focus on recurrent pericarditis (RP) provides clear opportunities for growth.
&#8220;As a result, we think KNSA shares are attractive from a valuation perspective, driven by both the commercial prospects of Arcalyst as well as the undervalued pipeline,&#8221; the analyst adds.
In February, Kiniksa Pharmaceuticals released a development update that said it would focus on cardiovascular indications.
<ul>
<li>The company discontinued abiprubart development in Sjögren&#8217;s Disease. The company will explore strategic alternatives for the asset.</li>
<li>Kiniksa also announced that it has exercised its right to terminate its exclusive license agreement for mavrilimumab with AstraZeneca Plc&#8216;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>) MedImmune.</li>
</ul>
Kiniksa is developing KPL-387 for recurrent pericarditis (RP) with a target profile of monthly <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/g43937097/kiniksa-pharmaceuticals-announces-development-of-kpl-387-in-recurrent-pericarditis-and-updates-cor" rel="noreferrer noopener">subcutaneous (SC) dosing</a>.
<ul>
<li>Recurrent pericarditis is&nbsp;a condition where the pericardium becomes inflamed again after a period of symptom-free time.&nbsp;The pericardium is a sac that surrounds the heart.&nbsp;</li>
<li>Kiniksa is conducting a single ascending dose (SAD) and multiple ascending dose Phase 1 trial of KPL-387 in healthy volunteers.</li>
<li>Kiniksa has interacted with the U.S. Food and Drug Administration (FDA) and expects to initiate a Phase 2/3 trial of KPL-387 in recurrent pericarditis in mid-2025. Phase 2 data are expected in the second half of 2026.</li>
</ul>
Arcalyst net product revenue was $122.5 million and $417.0 million for the fourth quarter and full year 2024, respectively. The company expects 2025 Arcalyst revenues of <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/g43937111/kiniksa-pharmaceuticals-reports-fourth-quarter-and-full-year-2024-financial-results-and-recent-por" rel="noreferrer noopener">$560 million-$580 million</a>.
Price Action: KNSA stock is down 1.6% at $21.04 at last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/government/regulations/25/03/44165513/taiwan-semiconductor-ceo-taiwan-president-to-discuss-100-billion-us-expansion-not-afraid-of-losing-us-subsidies" target="_blank" rel="noreferrer noopener">Taiwan Semiconductor CEO, Taiwan President To Discuss $100 Billion US Expansion, &#8216;Not Afraid&#8217; Of Losing US Subsidies</a></li>
</ul>
Photo: Shutterstock

KNSA

Kiniksa Pharmaceuticals Stock Is Attractive From Valuation Perspective-JP Morgan Analyst

Amgen Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>) has kicked off two crucial phase three trials for MariTide, its investigational weight loss injection. This move marks a significant step in the company&#8217;s pursuit to break into the growing market for obesity drugs.
What Happened: The MARITIME program, the drug&#8217;s phase three development program, is advancing remarkably well, said Dr. Jay Bradner, Amgen&#8217;s Executive Vice President of Research and Development at the 45th Annual TDCowen Healthcare Conference on Wednesday, as per <a href="https://www.cnbc.com/2025/03/05/amgen-weight-loss-drug-maritide-starts-two-phase-three-trials.html">CNBC</a>. MariTide, a monthly injection, is anticipated to rival the existing weekly weight loss injectables from Novo Nordisk&#8216;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) Ozempic and Wegovy and Eli Lilly&#8216;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) Zepbound. These medications belong to a class called GLP-1s, which mimic specific gut hormones to regulate appetite and blood sugar levels.
The initial trial in the new phase three series will evaluate MariTide in approximately 3,500 individuals with obesity or those who are overweight but do not have Type 2 diabetes. The second trial will evaluate MariTide in 999 patients who are obese or overweight and have Type 2 diabetes. Both studies are primarily focussed to measure the percentage of weight loss over 72 weeks.
In November, Amgen revealed that MariTide enabled obesity patients to lose an average of up to 20% of their weight over a year in a phase two trial, without reaching a weight loss plateau. However, these results did not meet Wall Street&#8217;s lofty expectations for the drug. Amgen&nbsp;is set to release&nbsp;additional information on MariTide this&nbsp;year.
SEE ALSO:<a href="https://www.benzinga.com/markets/equities/25/03/44157043/jim-cramer-doubles-down-on-crowdstrike-despite-drop-analysts-who-were-so-negativehad-it-wrong"> Jim Cramer Doubles Down On CrowdStrike Despite Drop: &#8216;Analysts Who Were So Negative…Had It Wrong&#8217;</a>
Why It Matters: According to Morgan Stanley Research, the global market for weight-loss drugs is projected to reach $105 billion by 2030. The obesity drug market is also highly competitive, with companies like&nbsp;Novo Nordisk&nbsp;recently enhancing access to its weight-loss medication, Wegovy, by lowering prices and <a href="https://www.benzinga.com/25/03/44143391/novo-nordisk-boosts-wegovy-access-with-lower-pricing-and-home-delivery">offering home delivery</a>. Amgen&#8217;s entry into this market with MariTide could potentially disrupt the current market dynamics.
Moreover, Amgen&#8217;s recent success with its <a href="https://www.benzinga.com/25/03/44083934/amgen-astrazeneca-partnered-asthma-drug-shows-rapid-and-sustained-effect-in-chronic-rhinosinusitis">partnered asthma drug </a>with&nbsp;AstraZeneca&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>) in treating chronic rhinosinusitis with nasal polyps, further underscores the company&#8217;s commitment to addressing significant health issues. The success of MariTide in the upcoming trials could further cement Amgen&#8217;s position in the pharmaceutical industry.
<ul>
<li>READ MORE: <a href="https://www.benzinga.com/news/25/03/44139027/aoc-rips-into-elon-musk-he-is-not-a-scientist-he-is-not-an-engineer-he-is-a-billionaire-con-man-with-a-lot-of-money">AOC Rips Into Elon Musk: &#8216;He Is Not A Scientist, He Is Not An Engineer. He Is A Billionaire Con Man With A Lot Of Money&#8217;</a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Markets

AMGN

Amgen Challenges Novo Nordisk's Ozempic And Eli Lilly's Zepbound As Its Monthly Weight Loss Drug MariTide Enters Two Late-Stage Trials

On Saturday, Amgen&nbsp;Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>) and AstraZeneca Plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>) announced full results from the Phase 3, registrational WAYPOINT trial evaluating the efficacy and safety of tezepelumab in adults with severe chronic rhinosinusitis <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/n44066175/positive-results-from-tezspire-tezepelumab-ekko-phase-3-waypoint-trial-highlight-rapid-sustained-e" rel="noreferrer noopener">with nasal polyps (CRSwNP)</a>.
The company released topline <a target="_blank" href="https://www.benzinga.com/general/biotech/24/11/41843534/astrazeneca-amgens-asthma-drug-aces-late-stage-study-in-patients-with-chronic-rhinosinusitis" rel="noreferrer noopener">data in November 2024</a>.
The data demonstrated that Tezspire&nbsp;(tezepelumab-ekko) significantly reduced nasal polyp severity, the need for surgery, and systemic corticosteroid use in CRSwNP (nasal polyps) patients compared to placebo.
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41756467/upstream-bio-is-new-on-nasdaq-can-potentially-beat-astrazenecas-asthma-drug-on-effi" rel="noreferrer noopener">Upstream Bio Is New On NASDAQ, Can Potentially Beat AstraZeneca&#8217;s Asthma Drug On Efficacy, Analysts Say</a>
Treatment with Tezspire significantly reduced nasal polyp severity: the Nasal Polyp Score (NPS) was -2.065, and the nasal congestion score was -1.028 at week 52 compared to placebo.
Improvements in NPS were observed as early as week four and nasal congestion as early as week two (the first post-treatment assessments, respectively) and were sustained through week 52.1
Statistically significant and clinically meaningful improvements were observed across all key secondary outcomes assessed in the overall trial population.
Tezspire significantly reduced the need for nasal polyp surgery by 98% and systemic corticosteroid treatment by 88% compared to placebo.
In patients with CRSwNP, Tezspire had a safety profile consistent with its approved severe asthma indication.
Tezspire is indicated for the add-on maintenance treatment of adult and pediatric patients aged 12 years and older with severe asthma.
Tezspire is not indicated for the relief of acute bronchospasm or status asthmaticus.
In May, Amgen&nbsp;and&nbsp;AstraZeneca announced the results of the Phase 2a COURSE trial of Tezspire&nbsp;for severe chronic <a target="_blank" href="https://www.benzinga.com/general/biotech/24/05/38924821/amgenastrazeneca-say-asthma-drug-shows-activity-in-another-lung-disease-across-broad-patient-popu" rel="noreferrer noopener">obstructive pulmonary disease</a>.
The primary results showed that treatment with Tezspire led to a 17% numerical reduction in the annual rate of moderate or severe COPD exacerbations compared to placebo at week 52, which was not statistically significant.
The proof-of-concept study showed that, in patients with BEC ≥150 cells/µL, tezepelumab led to a nominally significant reduction of 37% in the rate of moderate or severe exacerbations compared to placebo.
Price Action: AMGN stock traded higher by 0.77% to $310.51 at the last check on Monday. AZN stock is up 0.10% to $76.29 at the last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/25/02/44054480/archer-aviations-stellantis-deal-launch-program-strengthen-growth-prospects-faa-certification-looms" target="_blank" rel="noreferrer noopener">Archer Aviation&#8217;s Stellantis Deal, Launch Program Strengthen Growth Prospects, FAA Certification Looms</a></li>
</ul>
Photo via Shutterstock

Amgen-AstraZeneca Partnered Asthma Drug Shows Rapid And Sustained Effect In Chronic Rhinosinusitis

<ul>
<li>Phase 3 results confirm the efficacy of Daiichi Sankyo and AstraZeneca's ENHERTU in second-line metastatic gastric cancer</li>
<li>DESTINY-Gastric04 will be unblinded at interim analysis based on the superior efficacy of ENHERTU</li>
<li>Results will be shared with global regulatory authorities</li>
</ul>
Positive topline results from the <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT04704934&amp;esheet=54217318&amp;newsitemid=20250228334277&amp;lan=en-US&amp;anchor=DESTINY-Gastric04&amp;index=1&amp;md5=ad14a3495783683b7c506db635fea969">DESTINY-Gastric04</a> phase 3 trial showed ENHERTU&#xAE; (trastuzumab deruxtecan) demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of overall survival (OS) compared to ramucirumab and paclitaxel in patients with second-line HER2 positive (IHC 3+ or IHC 2+/ISH+) unresectable and/or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma.

Enhertu Releases Results In Overall Survival For HER2 Positive Metastatic Gastric Cancer In Destiny-Gastric04 Phase 3 Trial Interim Analysis

<ul>
<li>The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the pivotal <a href="https://www.astrazeneca.com/media-centre/press-releases/2023/imfinzi-based-treatment-before-and-after-surgery-reduced-the-risk-of-disease-recurrence-progression-events-or-death-in-resectable-non-small-cell-lung-cancer.html">AEGEAN</a> trial, which were published in <a href="https://www.nejm.org/">The New England Journal of Medicine</a>.</li>
<li>Results from a planned interim analysis of event-free survival (EFS) showed a statistically significant and clinically meaningful 32% reduction in the risk of recurrence, progression events or death versus neoadjuvant chemotherapy alone in patients treated with the Imfinzi-based perioperative regimen (32% data maturity; EFS hazard ratio [HR] 0.68; 95% confidence interval [CI] 0.53-0.88; p=0.003902). In a final analysis of pathologic complete response (pCR), treatment with Imfinzi plus neoadjuvant chemotherapy before surgery resulted in a pCR rate of 17.2% versus 4.3% for patients treated with neoadjuvant chemotherapy alone (difference in pCR 13.0%; 95% CI 8.7-17.6).</li>
<li>Additionally, interim overall survival (OS) results presented at the 2024 World Conference on Lung Cancer showed a favourable trend with the Imfinzi-based perioperative regimen (35% data maturity; median OS: not reached [NR] versus 53.2 months; HR=0.89; 95% CI 0.70-1.14). The OS data were not tested for statistical significance at this interim analysis and will continue to be assessed as a key secondary endpoint at final analysis.</li>
</ul>

AstraZeneca's Imfinzi (Durvalumab) In Combination With Chemotherapy Has Been Recommended For Approval In The European Union For Adult Patients With Resectable Non-small Cell Lung Cancer

<ul>
<li>TEZSPIRE significantly reduced nasal congestion, polyp size and nearly eliminated the need for surgery in patients with chronic rhinosinusitis with nasal polyps</li>
<li>WAYPOINT data published in New England Journal of Medicine and highlighted as late-breaking oral presentation at AAAAI/WAO 2025</li>
</ul>

Reported Saturday, Amgen And AstraZeneca TEZSPIRE Phase III Trial Confirms Rapid And Lasting Relief In Nasal Polyps, Cutting Surgery Risk By 98%

Nvidia Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) CEO Jensen Huang might be all-in on GPUs, but IonQ Inc's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IONQ#NYSE">IONQ</a>) CEO Niccolo De Masi <a href="https://www.benzinga.com/topic/quantum-computing">says quantum computing</a> is the next big thing—and he's not backing down.
<h2 class="wp-block-heading">Quantum: The Third Leg Of Computing</h2>
"I can remember 10 years ago when Intel was busy bashing Jensen and Nvidia and saying GPUs would never matter," De Masi <a href="https://www.cnbc.com/video/2025/02/27/ionq-ceo-on-quantum-computing-and-mechanics-ai.html">said</a> in a CNBC interview. "I find that ironic that our market cap is about the same as Nvidia's 10 years ago. Now, Jensen is saying that you don't matter."
IonQ stock may have had a rocky 2025—down 42% year-to-date—but over the past six months, the stock has skyrocketed 257.9%, signaling that investors are taking the quantum race seriously. 
De Masi is confident that quantum processing units (QPUs) will soon sit alongside CPUs and GPUs as the backbone of computing.
Read Also: <a href="https://www.benzinga.com/news/management/25/02/43993251/ionq-q4-eps-miss-500-million-offering-ceo-appointment-acquires-stake-in-id-quantique-details">IonQ Q4 EPS Miss, $500 Million Offering, CEO Appointment, Acquires Stake In ID Quantique: Details</a>
<h2 class="wp-block-heading">Revenue, Partnerships, Quantum's Real-World Impact</h2>
&#8220;Quantum computing needs a lot of qubits to be truly useful. We think it takes about that many to do this useful stuff that we're already driving GAAP revenue around this year." De Masi said. "We're the only company in the space that has guided to $85 million in GAAP revenue this year at the midpoint."
IonQ isn't just talking the talk, it. is securing major partnerships with industry giants like Microsoft Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>), AstraZeneca Plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>) and General Dynamics Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GD#NYSE">GD</a>).
"We're going to solve problems that no one else can solve in the world because of the beauty of quantum mechanics," De Masi said.
<h2 class="wp-block-heading">The 800-Pound Gorilla In Quantum Computing</h2>
With Nvidia dominating AI and Microsoft making heavy bets on quantum through Azure, IonQ is positioning itself as the independent leader in quantum computing. "We were the first. We were the best capitalized independent player in the market," De Masi stated. "I would argue that we remain the 800-pound gorilla of the category."
As tech giants continue to evolve their computing stacks, the question isn't whether quantum computing matters, it's when it will become indispensable. And IonQ is betting that moment is sooner than most expect.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/tech/25/02/44032246/sam-altman-calls-it-magic-as-openai-rolls-out-gpt-4-5-feels-like-talking-to-a-thoughtful-person-to-me">Sam Altman Calls It &#8216;Magic&#8217; As OpenAI Rolls Out GPT-4.5: &#8216;Feels Like Talking To A Thoughtful Person To Me&#8217;</a></li>
</ul>
Photo: Shutterstock

Long Ideas

Tech

Interview

IONQ

MSFT

NVDA

IonQ CEO Fires Back At Nvidia's Jensen Huang: 'We Remain The 800 Pound Guerrilla'

Snowflake Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNOW#NYSE">SNOW</a>) unveiled its deeper partnership with Microsoft Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) during its earnings call after reporting <a href="https://www.benzinga.com/news/earnings/25/02/43991826/snowflake-beats-q4-estimates-expands-microsoft-partnership-to-include-openai-models">better-than-expected</a> fourth-quarter results. The data cloud company introduced its new artificial intelligence agent Cortex for enhanced productivity and data access.
What Happened: The company announced that it has expanded its partnership with Microsoft, which brings OpenAI&#8217;s models into Cortex.
Cortex Agents are a new class of AI agents from Snowflake that can perform a variety of business tasks using structured and unstructured data. Cortex is also powered by other large language models.
&#8220;We are supporting a range of market-leading models, including Anthropic&#8217;s Claude, Meta Llama, and DeepSeek,&#8221; said CEO Sridhar Ramaswamy.
The CEO also added, &#8220;We are making Cortex Agents available in Microsoft 365 CoPilot and Microsoft Teams, bringing millions of users, seamless access to information, and accelerated productivity, all within the Microsoft platform.&#8221;
During the earnings call, Ramaswamy highlighted how AstraZeneca PLC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>) is using Snowflake&#8217;s AI and machine learning technology to, accelerate drug discovery and development, aiming for 20 new medicines by 2030.
He also explained that State Street Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STT#NYSE">STT</a>) leverages Snowflake AI to uncover market insights for better investment decisions.
See Also: <a href="https://www.benzinga.com/general/market-summary/25/02/43998226/jensen-huangs-nvidia-fuels-ai-factory-boom-revenue-growth-in-data-center-business-dominates-peers-with-a-staggering-3460-growth-over-5-years">Jensen Huang&#8217;s Nvidia Fuels &#8216;AI Factory&#8217; Boom: Revenue Growth In Data Center Business Dominates Peers With A Staggering 3460% Growth Over 5 Years</a>
Why It Matters: Snowflake beat analyst expectations in its latest quarterly results. Earnings per share came in at 30 cents, significantly exceeding the 17 cents per share predicted by analysts. Revenue also soared to $986.77 million, surpassing the anticipated $955.93 million and marking a substantial jump from $774.7 million in the same period last year.
Despite the strong performance, Snowflake&#8217;s future projections fell short of analyst expectations. The company anticipates first-quarter revenue between $955 million and $960 million, lower than the $1 billion estimate. For fiscal 2026, Snowflake projects revenue of $4.28 billion, missing the $4.41 billion estimate.
Price Action: SNOW rose 1.21% on Wednesday and jumped 9.06% in after-hours, this outpaced the 0.05% rise in the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>), which tracks the S&amp;P 500 index.
The stock remains 5.51% higher on a year-to-date basis and down 28.99% over a year.
<a href="https://www.benzinga.com/quote/SNOW/analyst-ratings">Benzinga tracks 38 analysts</a> with an average price target of $193.42 for the stock, reflecting a &#8220;buy&#8221; rating. Estimates range widely from $121 to $235. Recent ratings from Rosenblatt, Citigroup, and Canaccord Genuity average $218.33, suggesting a potential 20.46% upside.
<figure class="wp-block-image size-large"><a href="https://www.benzinga.com/quote/SNOW/analyst-ratings"><img loading="lazy" decoding="async" width="1024" height="381" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/27025756/SNOW-ANR-1024x381.png" alt="" class="wp-image-800957" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/27025756/SNOW-ANR-1024x381.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/27025756/SNOW-ANR-300x112.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/27025756/SNOW-ANR-768x286.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/27025756/SNOW-ANR.png 1059w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/market-summary/25/02/43969651/billionaire-ray-dalio-says-ai-risks-totalitarian-control-or-anarchy-as-it-could-reshape-world-in-next-5-years-here-is-a-list-of-ai-linked-etfs-for-investors-to-consider">Billionaire Ray Dalio Says AI Risks &#8216;Totalitarian Control Or Anarchy&#8217; As It Could Reshape World In Next 5 Years: Here Are AI-Linked ETFs For Investors To Consider</a></li>
</ul>
Photo courtesy: Shutterstock

Earnings

Equities

Market Summary

SNOW

Snowflake Expands Microsoft, OpenAI Partnership: Will Include Other Prominent Models Like Anthropic's Claude, Meta's Llama, And DeepSeek

On Wednesday, AstraZeneca Plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>) released high-level results from a planned interim analysis of the SERENA-6 Phase 3 trial.
SERENA-6 is <a target="_blank" href="https://www.astrazeneca.com/media-centre/press-releases/2025/camizestrant-improved-pfs-in-1l-hr-breast-cancer.html" rel="noreferrer noopener">evaluating</a> the efficacy and safety of camizestrant in combination with a CDK4/6 inhibitor (palbociclib, ribociclib or abemaciclib) versus treatment with an AI (anastrozole or letrozole) in combination with a CDK4/6 inhibitor for HR-positive, HER2-negative advanced breast cancer whose tumors have an emergent&nbsp;ESR1 mutation.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/02/43859578/amid-mounting-pressure-in-china-astrazeneca-buys-fibrogens-chinese-unit-for-160-million-and-gains-access-to-anemia-drug" rel="noreferrer noopener">Amid Mounting Pressure In China, AstraZeneca Buys FibroGen&#8217;s Chinese Unit For $160 Million</a>
The data showed that the camizestrant combination regime demonstrated a statistically significant and clinically meaningful improvement in the progression-free survival (PFS) endpoint.
The key secondary endpoints of time-to-second disease progression (PFS2) and overall survival (OS) were immature at the time of this interim analysis.
However, the camizestrant combination demonstrated a trend toward improvement in PFS2. The safety profile of&nbsp;camizestrant&nbsp;in combination with palbociclib, ribociclib or abemaciclib in SERENA-6 was consistent with the known safety profile of each medicine.
No new safety concerns were identified, and discontinuations were very low and similar in both arms.
Earlier this month,&nbsp;AstraZeneca shared&nbsp;results from a post-hoc exploratory subgroup analysis from the <a target="_blank" href="https://www.benzinga.com/25/02/43742302/astrazenecas-imfinzi-perioperative-regimen-shows-improved-survival-outcomes-in-bladder-cancer-patients" rel="noreferrer noopener">NIAGARA Phase 3 trial</a>.
The study showed that Imfinzi&nbsp;(durvalumab), administered perioperatively in combination with neoadjuvant (before surgery) chemotherapy, demonstrated improvements in event-free survival and overall survival versus neoadjuvant chemotherapy with radical cystectomy alone in patients with or without a pathologic complete response in muscle-invasive bladder cancer.
Price Action: AZN stock is up 0.68% at $75.93 at the last check on Wednesday.
Read Next
<ul>
<li><a href="https://www.benzinga.com/25/02/43970279/alibaba-and-deepseek-intensify-ai-showdown-challenging-openai-and-nvidias-market-dominance" target="_blank" rel="noreferrer noopener">Alibaba And DeepSeek Intensify AI Showdown, Challenge OpenAI Market Dominance</a></li>
</ul>
Image by Robert Way via Shutterstock

AstraZeneca's Investigational Cancer Drug Shows First-Line Benefit In Combination With Widely Cancer Medicines

Positive high-level results from a planned interim analysis of the SERENA-6 Phase III trial showed that AstraZeneca's camizestrant&nbsp;in combination with a&nbsp;cyclin-dependent kinase (CDK) 4/6 inhibitor (palbociclib, ribociclib or abemaciclib) demonstrated a highly statistically significant and clinically meaningful improvement in the primary endpoint of progression-free survival (PFS). The trial evaluated&nbsp;switching to&nbsp;the camizestrant combination&nbsp;versus continuing standard-of-care treatment with an aromatase inhibitor (AI) (anastrozole or letrozole) in combination&nbsp;with a CDK4/6 inhibitor in the 1st-line treatment of patients with&nbsp;hormone receptor (HR)-positive, HER2-negative advanced breast cancer whose tumours have an emergent&nbsp;ESR1&nbsp;mutation.
&nbsp;
The key secondary endpoints of time to second disease progression (PFS2) and overall survival (OS) were immature at the time of this interim analysis. However, the camizestrant combination demonstrated a trend toward improvement in PFS2. The trial will continue as planned to further assess key secondary endpoints.
&nbsp;
SERENA-6 is the first global, double-blind, registrational Phase III trial to use a circulating tumour DNA (ctDNA)-guided approach to detect the emergence of endocrine resistance and inform a switch in therapy before disease progression. The novel trial design used ctDNA monitoring at the time of routine tumour scan visits to identify patients for early signs of endocrine resistance and the emergence of&nbsp;ESR1&nbsp;mutations. Following detection of an&nbsp;ESR1&nbsp;mutation without disease progression, the endocrine therapy of patients was switched to camizestrant from ongoing treatment with an AI, while continuing combination with the same CDK4/6 inhibitor.

AstraZeneca's SERENA-6 Study Assesses Camizestrant for HR-Positive Breast Cancer, Key Outcomes Awaited

Legal

VKTX

Drug Compounders Sue U.S. Drug Regulator Over Removal Of Novo Nordisk Diabetes, Weight Loss Drugs From Shortage List

<a href="https://www.dailymail.co.uk/galleries/article-14422269/New-coronavirus-pandemic-potential-discovered-China.html">https://www.dailymail.co.uk/galleries/article-14422269/New-coronavirus-pandemic-potential-discovered-China.html</a>
&nbsp;

Macro Economic Events

Global

Economics

NVAX

'New Coronavirus With Pandemic Potential Discovered In China' - DailyMail

DRIO

Hims & Hers Health, Inc. Class A Common Stock

HIMS

LFVN

RHHBY

TERN

FDA Says Novo Nordisk's Ozempic Injection .68 mg/1 ml, Injection 1.34 mg/1 ml, Injection 2.68 Mg/1 ml Available As Of Feb 21; Novo Nordisk's Wegovy, Injection, 1.7 mg/.75 ml , Wegovy, Injection, 2.4 mg/.75 ml Now Available; FDA Says Semaglutide Injection Shortage Is Resolved As Of Feb 21

Press Releases

Lost Money on AstraZeneca PLC(AZN)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky

FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of AstraZeneca

AstraZeneca PLC Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before February 21, 2025 to Discuss Your Rights – AZN

Leading Healthcare Institutions Adopt MSK-ACCESS® for Liquid Biopsy Testing

AstraZeneca PLC Investors: Please contact the Portnoy Law Firm to recover your losses. February 21, 2025 Deadline to file Lead Plaintiff Motion

Camizestrant demonstrated highly statistically significant and clinically meaningful improvement in progression-free survival in 1st-line advanced HR-positive breast cancer with an emergent ESR1 tumor mutation in SERENA-6 Phase III trial

Positive results from the TEZSPIRE Phase III WAYPOINT trial highlight rapid and sustained effect in chronic rhinosinusitis with nasal polyps

ENHERTU® Demonstrated Statistically Significant and Clinically Meaningful Improvement in Overall Survival in Patients with HER2 Positive Metastatic Gastric Cancer at Interim Analysis of DESTINY-Gastric04 Phase 3 Trial

IMFINZI® (durvalumab)-based regimen demonstrated statistically significant and clinically meaningful improvement in event-free survival in resectable early-stage gastric and gastroesophageal junction cancers

AstraZeneca and Erin Andrews team up to inspire fans to Get Body Checked Against Cancer

SOPH

TYO:4568

Amneal Pharmaceuticals, Inc. - Class A Common Stock

Amneal Pharmaceuticals

Axsome Therapeutics

Bristol-Myers Squibb Company Common Stock

Bristol-Myers Squibb

Corcept Therapeutics Incorporated - Common Stock

Corcept Therapeutics

Elanco Animal Health Incorporated Common Stock

Elanco Animal Health

GSK plc American Depositary Shares (Each representing two Ordinary Shares)

Haleon plc American Depositary Shares (Each representing two Ordinary Shares)

Haleon

Intra-Cellular Therapies Inc. - Common Stock

Intra-Cellular Therapies

Jazz Pharmaceuticals plc - Ordinary Shares

Jazz Pharmaceuticals

Johnson & Johnson

Eli Lilly

Merck & Co

Novo Nordisk

Novartis

Organon

Prestige Consumer Healthcare Inc. Common Stock

Prestige Consumer

Pfizer

Dr. Reddy's Laboratories Ltd Common Stock

Dr Reddy's Laboratories

Royalty Pharma plc - Class A Ordinary Shares

Royalty Pharma

Sanofi

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)

Takeda Pharmaceutical Co

Teva Pharmaceutical Industries Limited American Depositary Shares

Teva Pharmaceutical Indus

Verona Pharma plc - American Depositary Shares

Verona Pharma

Viatris

Zoetis

TD Cowen

Argus Research

Goldman Sachs

BMO Capital

Morgan Stanley

Screenshot 2024-09-30 at 9.13.36 PM

TNXP

VRTX

The Rush For Non-Addictive Painkillers To Counter The Opioid Crisis Puts Two Companies Closer To FDA Decisions

Screenshot 2024-09-30 at 5.38.54 PM

Movers & Shakers

COSM

Nestle Sponsored representing Registered Shares Series B

NSRGY

VTRS

How Cosmos Health&#39;s Acquisition Of Almost 100-Year-Old Company, Adding To Capabilities Like Contract Manufacturing, Could Generate Over $10 Million In Annual Gross Profit

Comments

AstraZeneca

空売り

AstraZeneca (NASDAQ:AZN) 株価情報, 空売り情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル